Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialYung‐Jue Bang, Yoon‐Koo Kang, Eric Van Cutsem et al.|The Lancet|2010Cited by 7.3k
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Jaffer A. Ajani, Florian Lordick et al.|The Lancet|2023Cited by 701
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and IrinotecanChiara Cremolini, Daniele Santini, Domenico Corsi et al.|JAMA Oncology|2018Cited by 418
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al.|The Lancet Oncology|2020Cited by 322
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Marcello Gambacorta, Cosimo Martino et al.|Modern Pathology|2015Cited by 317